

FIG 1




FIG 2




FIG 3







FIG 4




**BRI6727**




**BRI6728**



**BRI6734**




**BRI6813**




**BRI6795**


**FIG 5A**




**BRI6796**




**BRI6797**



**BRI6798**




**BRI6799**




**BRI6800**

**FIG 5B**


09995277.112601




BRI6801




BRI6802



BRIX114




BRI6803




BRI6814


FIG 5C




**BRI6815**




**BRI6816**



**BRI6817**




**BRI6822**




**BRI6823**

**FIG 5D**







**BRI6824**




**BRI6825**



**BRI6829**



**BRI6855**



**BRI6856**

**FIG 5E**










FIG 5F




**BRI7009**



**BRI7012**

**FIG 5G**


# Inhibition or enhancement of FcγRIIIa binding to human IgG1.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 6


# Inhibition or enhancement of FcγRIIIa binding to human IgG3.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 7


# Inhibition or enhancement of FcγRIIIa binding to human IgG1.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 8

# Inhibition or enhancement of FcγRIIIa binding to human IgG3.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 9

Enhanced sFcγRII binding




FIG 10



709277-225666

Inhibition of sFcγRIIIa binding






FIG 11



Activation of platelets in the presence of agonist only.  
 Platelets ( $100 \times 10^6/\text{ml}$ ) were mixed in the presence of Fc $\gamma$ RIIIa agonist (HAGG,  $200 \mu\text{g}/\text{ml}$ ) and PBS and the rate of platelet aggregation was measured as the gradient of the change to percent light transmission (x) over time (y).

FIG 12



Activation of platelets in the presence of agonist and BRI compound 6855. Platelets ( $100 \times 10^6/\text{ml}$ ) were mixed in the presence of Fc $\gamma$ RIIa agonist (HAGG,  $200 \mu\text{g}/\text{ml}$ ) and compound BRI 6855 ( $5 \text{ mg}/\text{ml}$ ) and the rate of platelet aggregation was measured as the gradient of the change to percent light transmission (x) over time (y).

FIG 13

Effect of BRI compound 6728 on platelet aggregation with HAGG




FIG 14